Barclays Begins Coverage on Inventiva (NASDAQ:IVA)

Equities research analysts at Barclays initiated coverage on shares of Inventiva (NASDAQ:IVA) in a note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $18.00 price target on the stock. Barclays‘s price target points to a potential upside of 163.54% from the stock’s current price.

Several other research firms have also commented on IVA. HC Wainwright set a $24.00 price objective on Inventiva and gave the stock a “buy” rating in a research note on Wednesday. Wolfe Research upgraded Inventiva to a “strong-buy” rating in a research report on Thursday, November 6th. Guggenheim decreased their price objective on Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research note on Thursday, January 22nd. Finally, UBS Group started coverage on shares of Inventiva in a report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Inventiva presently has an average rating of “Buy” and an average target price of $16.22.

Inventiva Stock Down 0.6%

Shares of IVA stock opened at $6.83 on Tuesday. Inventiva has a 12 month low of $2.18 and a 12 month high of $7.98. The company has a 50 day simple moving average of $4.96 and a two-hundred day simple moving average of $4.77.

Institutional Trading of Inventiva

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Creative Planning bought a new position in Inventiva in the 2nd quarter worth approximately $32,000. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Inventiva by 54.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after buying an additional 5,843 shares in the last quarter. NewEdge Advisors LLC bought a new position in shares of Inventiva during the third quarter worth $116,000. Finally, Millennium Management LLC purchased a new position in Inventiva during the third quarter valued at $649,000. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.